Compare CINT & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CINT | SPRY |
|---|---|---|
| Founded | 1995 | 2015 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 391.6M | 404.8M |
| IPO Year | 2021 | 2020 |
| Metric | CINT | SPRY |
|---|---|---|
| Price | $3.11 | $4.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 4 |
| Target Price | $5.62 | ★ $22.50 |
| AVG Volume (30 Days) | 55.4K | ★ 1.4M |
| Earning Date | 11-11-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $84,278,000.00 |
| Revenue This Year | $16.56 | $54.14 |
| Revenue Next Year | $9.87 | $46.73 |
| P/E Ratio | $17.94 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.80 | $4.00 |
| 52 Week High | $6.06 | $13.15 |
| Indicator | CINT | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 46.66 | 40.41 |
| Support Level | $2.81 | $4.00 |
| Resistance Level | $3.62 | $4.57 |
| Average True Range (ATR) | 0.16 | 0.27 |
| MACD | 0.02 | 0.07 |
| Stochastic Oscillator | 46.03 | 32.28 |
CI&T Inc operates as a partner in tech-integrated business solutions, helping organizations address complex challenges by integrating business approach, technology, and artificial intelligence into a single, coherent operating model. It is mainly engaged in the development of customizable software through the implementation of software solutions, including machine learning, artificial intelligence, data analytics, cloud migration and mobility technologies. The company provides technology services to various industry verticals, including Financial Services, Consumer Goods, Technology and Communications, Retail and Industrial Goods, Life Sciences, among others. The majority of the revenue is derived from providing technology services. Geographically, maximum revenue is derived from Brazil.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.